AU2015352440B2 - Compounds - Google Patents

Compounds Download PDF

Info

Publication number
AU2015352440B2
AU2015352440B2 AU2015352440A AU2015352440A AU2015352440B2 AU 2015352440 B2 AU2015352440 B2 AU 2015352440B2 AU 2015352440 A AU2015352440 A AU 2015352440A AU 2015352440 A AU2015352440 A AU 2015352440A AU 2015352440 B2 AU2015352440 B2 AU 2015352440B2
Authority
AU
Australia
Prior art keywords
compound
formula
compounds
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015352440A
Other languages
English (en)
Other versions
AU2015352440A1 (en
Inventor
Steven Boakes
Pamela Brown
Michael Dawson
Esther DUPERCHY
Stephen Frederick Moss
Mona SIMONOVIC
Steven James Stanway
Antoinette Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spero Therapeutics Inc
Original Assignee
Spero Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1421020.7A external-priority patent/GB201421020D0/en
Priority claimed from GBGB1516059.1A external-priority patent/GB201516059D0/en
Application filed by Spero Therapeutics Inc filed Critical Spero Therapeutics Inc
Publication of AU2015352440A1 publication Critical patent/AU2015352440A1/en
Assigned to SPERO THERAPEUTICS, INC. reassignment SPERO THERAPEUTICS, INC. Request for Assignment Assignors: NEW PHARMA LICENCE HOLDINGS LIMITED
Application granted granted Critical
Publication of AU2015352440B2 publication Critical patent/AU2015352440B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015352440A 2014-11-26 2015-11-26 Compounds Active AU2015352440B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1421020.7 2014-11-26
GBGB1421020.7A GB201421020D0 (en) 2014-11-26 2014-11-26 Compounds
GB1516059.1 2015-09-10
GBGB1516059.1A GB201516059D0 (en) 2015-09-10 2015-09-10 Compounds
PCT/EP2015/077821 WO2016083531A1 (en) 2014-11-26 2015-11-26 Compounds

Publications (2)

Publication Number Publication Date
AU2015352440A1 AU2015352440A1 (en) 2017-06-29
AU2015352440B2 true AU2015352440B2 (en) 2020-02-06

Family

ID=54705181

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015352440A Active AU2015352440B2 (en) 2014-11-26 2015-11-26 Compounds

Country Status (8)

Country Link
US (2) US12146004B2 (enExample)
EP (1) EP3224273A1 (enExample)
JP (1) JP7349773B2 (enExample)
CN (1) CN107108699A (enExample)
AU (1) AU2015352440B2 (enExample)
CA (1) CA2968902C (enExample)
TW (1) TWI757229B (enExample)
WO (1) WO2016083531A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3224273A1 (en) * 2014-11-26 2017-10-04 New Pharma Licence Holdings Limited Compounds
WO2018006063A1 (en) * 2016-07-01 2018-01-04 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
AU2017376711B2 (en) * 2016-12-16 2020-07-16 Institute Of Medicinal Biotechnology, Chinese Academy Of Medical Sciences Polymyxin derivative, preparation method and application thereof
US11279733B2 (en) 2017-11-02 2022-03-22 The University Of Queensland Peptide antibiotics
PL3810633T3 (pl) * 2018-06-25 2024-04-08 Spero Therapeutics, Inc. Związki
CN111690040A (zh) * 2019-03-12 2020-09-22 上海来益生物药物研究开发中心有限责任公司 多粘菌素衍生物、其制备方法和应用
WO2021150792A1 (en) 2020-01-21 2021-07-29 Micurx Pharmaceuticals, Inc. Novel compounds and composition for targeted therapy of kidney-associated cancers
CN111559992B (zh) * 2020-05-29 2022-04-08 华中科技大学 一种2-芳基-γ-氨基丁酸衍生物的制备方法
TW202233649A (zh) 2020-11-06 2022-09-01 美商斯佩羅治療學股份有限公司 化合物
WO2022206826A1 (zh) * 2021-03-31 2022-10-06 江苏奥赛康药业有限公司 一种多粘菌素衍生物的硫酸盐及其药物组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051663A1 (en) * 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2015149131A1 (en) * 2014-04-01 2015-10-08 Monash University Polymyxin derivatives as antimicrobial compounds

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
AU7753787A (en) 1986-08-06 1988-02-24 Jean-Luc Fauchere Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
TW274552B (enExample) 1992-05-26 1996-04-21 Hoechst Ag
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
CA2540742A1 (en) 2003-09-30 2005-04-14 Terry Hicks Compositions and methods for treating burns
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
CN103059106B (zh) 2006-08-11 2015-01-14 北方抗生素有限公司 多粘菌素衍生物及其用途
US7807637B2 (en) * 2006-08-11 2010-10-05 Northern Antibiotics Oy Polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
FI20085469A0 (fi) 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
ES2334547B1 (es) 2008-09-10 2010-12-03 Universidad De Barcelona Compuestos peptidicos antibacterianos.
US8343912B2 (en) 2008-12-23 2013-01-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (en) * 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012168820A1 (en) * 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
WO2013072695A1 (en) * 2011-11-18 2013-05-23 Novacta Biosystems Limited Polymyxin derivatives
PL2999711T3 (pl) 2013-05-22 2022-09-26 Spero Therapeutics, Inc. Pochodne polimyksyny i ich zastosowanie w terapii skojarzonej razem z różnymi antybiotykami
LT3116897T (lt) 2014-03-11 2022-05-10 Spero Therapeutics, Inc. Polimiksino dariniai ir jų panaudojimas kompleksinėje terapijoje kartu su skirtingais antibiotikais
EP3224273A1 (en) * 2014-11-26 2017-10-04 New Pharma Licence Holdings Limited Compounds
WO2016166103A1 (en) 2015-04-13 2016-10-20 Xellia Pharmaceuticals Aps Polymyxin derivatives
AU2016331658B2 (en) 2015-09-29 2021-04-01 Monash University Antimicrobial polymyxin derivative compounds
PL3810633T3 (pl) 2018-06-25 2024-04-08 Spero Therapeutics, Inc. Związki

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012051663A1 (en) * 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
WO2015149131A1 (en) * 2014-04-01 2015-10-08 Monash University Polymyxin derivatives as antimicrobial compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KAZUSHI KANAZAWA ET AL, "Contribution of Each Amino Acid Residue in Polymyxin B3 to Antimicrobial and Lipopolysaccharide Binding Activity", CHEMICAL AND PHARMACEUTICAL BULLETIN, JP, (2009-01-01), vol. 57, no. 3, pages 240 - 244 *
TONY VELKOV ET AL, "Teaching 'Old' Polymyxins New Tricks: New-Generation Lipopeptides Targeting Gram-Negative 'Superbugs'", ACS CHEMICAL BIOLOGY, US, (2014-05-16), vol. 9, no. 5, doi:10.1021/cb500080r, ISSN 1554-8929, pages 1172 - 1177 *

Also Published As

Publication number Publication date
JP7349773B2 (ja) 2023-09-25
AU2015352440A1 (en) 2017-06-29
WO2016083531A1 (en) 2016-06-02
CA2968902C (en) 2023-08-29
US20180030092A1 (en) 2018-02-01
TW201625664A (zh) 2016-07-16
EP3224273A1 (en) 2017-10-04
US20230340026A1 (en) 2023-10-26
US12146004B2 (en) 2024-11-19
CN107108699A (zh) 2017-08-29
JP2017538692A (ja) 2017-12-28
CA2968902A1 (en) 2016-06-02
TWI757229B (zh) 2022-03-11

Similar Documents

Publication Publication Date Title
AU2019264537A1 (en) Beta-lactamase inhibitors
AU2015352440B2 (en) Compounds
PH12017500408B1 (en) Heteroaryl compounds as btk inhibitors and uses thereof
EP3209653A4 (en) Process for the preparation of (r,s)-nicotine
WO2016011390A8 (en) Irak4 inhibiting agents
GEP20186933B (en) Substituted dihydroisoquinoline compounds
WO2015003816A3 (en) Cystobactamides
MX2016016143A (es) Compuestos de [1,2,4]triazol sustituido.
TN2019000211A1 (en) Antitumoral compounds
PH12015501588A1 (en) Compounds and methods for treating bacterial infections
MX2016003482A (es) Composiciones antimicrobianas.
PH12016501252A1 (en) Novel tetrahydropyridopyrimidine compound or salt thereof
EA033460B1 (ru) Замещенные [1,2,4]триазольные соединения в качестве фунгицидов
NZ731344A (en) Hydroxyl purine compounds and applications thereof
MY202127A (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
PH12017501071A1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
MX382092B (es) Compuestos heterocíclicos para el tratamiento de enfermedades.
NZ730816A (en) Quinoline carboxamides for use in the treatment of multiple myeloma
NZ732704A (en) Quinoline carboxamides for use in the treatment of leukemia
WO2016100302A3 (en) Solid forms comprising (1e, 4e)-2-amino-n,n-dipropyl-8-(4-(pyrrolidine-1-carbonyl)phenyl)-3h-benzo[b]azepine-4-carboxamide, compositions thereof, and uses thereof
IN2013MU03216A (enExample)
EP3251682A4 (en) Compositions for treating infections caused by the mite demodex spp
WO2016073652A8 (en) Iminosugars useful for the treatment of viral diseases
EP3148538A4 (en) Cenicriviroc for the treatment of hiv-2 infection

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: SPERO THERAPEUTICS, INC.

Free format text: FORMER APPLICANT(S): NEW PHARMA LICENCE HOLDINGS LIMITED

FGA Letters patent sealed or granted (standard patent)